home / stock / vcnx / vcnx news

VCNX News and Press, Vaccinex Inc. From 01/04/22

Stock Information
Company Name: Vaccinex Inc.
Stock Symbol: VCNX
Market: NASDAQ
Website: vaccinex.com
Menu
VCNX VCNX Quote VCNX Short VCNX News VCNX Articles VCNX Message Board
Get VCNX Alerts

News, Short Squeeze, Breakout and More Instantly...
VCNX - Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis

Phase 1b segment evaluated safety and tolerability of the combination Paves the way to expand and accelerate enrollment in the Phase 2 segment of the study ROCHESTER, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-s...
VCNX - Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

ROCHESTER, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Dr. Elizabeth Evans, PhD, Chi...

VCNX - Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer's Disease (CTAD) Meeting

ROCHESTER, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Terrence Fisher, Ph.D., Vice ...

VCNX - Vaccinex reports Q3 results

Vaccinex (NASDAQ:VCNX): Q3 GAAP EPS of -$0.17. Revenue of $50K (-92.0% Y/Y) Shares -2.97% PM. Press Release Cash and cash equivalents and marketable securities on September 30, 2021 were $13.8M For further details see: Vaccinex reports Q3 results

VCNX - Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Enrollment underway in combination Phase 1b/2 study of pepinemab with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patient screening and enrollment underway in Phase 1/2a study of pepinemab in Alzheimer’s disease Engaged in partneri...

VCNX - Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference

Virtual Dates: November 18 th – 19 th , 2021 ROCHESTER, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative diseas...

VCNX - Vaccinex to Present at the Virtual Huntington's Study Group Meeting on November 4-6, 2021

ROCHESTER, N.Y., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Maurice Zauderer, Ph.D., Pres...
VCNX - Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit

ROCHESTER, N.Y., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, a potent biological mediator, today announced tha...

VCNX - Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntington's Disease Network Meeting

ROCHESTER, N.Y., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, a potent biological mediator, today announced tha...

VCNX - Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Patients are currently being screened and enrolled in two studies of pepinemab as monotherapy in Alzheimer’s disease and in combination with KEYTRUDA ® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Ended the second quarter with cash and cash equival...
Previous 10 Next 10